Alpha-synuclein degradation by serine protease neurosin: implication for pathogenesis of synucleinopathies
- PMID: 12928483
- DOI: 10.1093/hmg/ddg283
Alpha-synuclein degradation by serine protease neurosin: implication for pathogenesis of synucleinopathies
Abstract
Accumulation of insoluble alpha-synuclein aggregates in the brain is characteristic of Parkinson's disease, dementia with Lewy bodies and multiple system atrophy. Although numerous studies on the aggregation properties of alpha-synuclein have been reported, little is known about its degradation so far. In view of proteolytic degradation, we have found that the serine protease neurosin (kallikrein-6) degrades alpha-synuclein and co-localizes with pathological inclusions such as Lewy bodies and glial cytoplasmic inclusions. In vitro study showed that neurosin prevented alpha-synuclein polymerization by reducing the amount of monomer and also by generating fragmented alpha-synucleins that themselves inhibited the polymerization. Upon cellular stress, neurosin was released from mitochondria to the cytosol, which resulted in the increase of degraded alpha-synuclein species. Down-regulation of neurosin caused accumulation of alpha-synuclein within cultured cells. Thus we concluded that neurosin plays a significant role in physiological alpha-synuclein degradation and also in the pathogenesis of synucleinopathies.
Similar articles
-
[Alpha-synucleinopathies].Neurologia. 2001 Apr;16(4):163-70. Neurologia. 2001. PMID: 11412709 Review. Spanish.
-
Extracellular neurosin degrades α-synuclein in cultured cells.Neurosci Res. 2010 Aug;67(4):341-6. doi: 10.1016/j.neures.2010.04.008. Epub 2010 Apr 18. Neurosci Res. 2010. PMID: 20403393
-
Cleavage of normal and pathological forms of alpha-synuclein by neurosin in vitro.Neurosci Lett. 2008 May 2;436(1):52-6. doi: 10.1016/j.neulet.2008.02.057. Epub 2008 Mar 4. Neurosci Lett. 2008. PMID: 18358605
-
Aggregation of alpha-synuclein in the pathogenesis of Parkinson's disease.J Neurol. 2003 Oct;250 Suppl 3:III11-4. doi: 10.1007/s00415-003-1303-x. J Neurol. 2003. PMID: 14579119
-
Neuropathological spectrum of synucleinopathies.Mov Disord. 2003 Sep;18 Suppl 6:S2-12. doi: 10.1002/mds.10557. Mov Disord. 2003. PMID: 14502650 Review.
Cited by
-
Analysis and comparison of post-translational modifications of α-synuclein filaments in multiple system atrophy and dementia with Lewy bodies.Sci Rep. 2024 Oct 2;14(1):22892. doi: 10.1038/s41598-024-74130-z. Sci Rep. 2024. PMID: 39358446 Free PMC article.
-
Lentivirus mediated delivery of neurosin promotes clearance of wild-type α-synuclein and reduces the pathology in an α-synuclein model of LBD.Mol Ther. 2013 Jan;21(1):31-41. doi: 10.1038/mt.2012.66. Epub 2012 Apr 17. Mol Ther. 2013. PMID: 22508489 Free PMC article.
-
Role of α-synuclein in inducing innate and adaptive immunity in Parkinson disease.J Parkinsons Dis. 2015;5(1):1-19. doi: 10.3233/JPD-140491. J Parkinsons Dis. 2015. PMID: 25588354 Free PMC article. Review.
-
Unleashing the therapeutic potential of human kallikrein-related serine proteases.Nat Rev Drug Discov. 2015 Mar;14(3):183-202. doi: 10.1038/nrd4534. Epub 2015 Feb 20. Nat Rev Drug Discov. 2015. PMID: 25698643 Review.
-
α-Synuclein posttranslational modification and alternative splicing as a trigger for neurodegeneration.Mol Neurobiol. 2013 Apr;47(2):509-24. doi: 10.1007/s12035-012-8330-5. Epub 2012 Aug 25. Mol Neurobiol. 2013. PMID: 22923347 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous